ERBB2 and breast carcinoma: In line with MEDICA effect in suppressing ErbB family members in transgenic ErbB2 breast cancer mice in vivo (Fig. 1b), loss of ErbB members and suppression of their respective transduction pathways were further verified in AU565 and BT474 human breast cancer cells.